Full-Time
Confirmed live in the last 24 hours
Develops and commercializes prescription medicines
No salary listed
Mid, Senior
Sant Cugat del Vallès, Barcelona, Spain
On-site commitment of three days a week.
AstraZeneca develops and sells prescription medicines, focusing on three main areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are created through extensive research and development, which includes clinical trials and regulatory approvals. Unlike many competitors, AstraZeneca emphasizes collaboration through its Open Innovation program and the A.Catalyst Network, which connects health innovation hubs worldwide. The company's goal is to advance healthcare by providing effective treatments for serious diseases.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3), underscoring its leadership in oncology through a diverse and robust pipeline.
21 May 2025Director DeclarationAstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed a director of Agilent Technologies Inc. with effect from 21 May 2025.This announcement is made pursuant to Listing Rule 6.4.9 (2).AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZenecaContactsFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.Matthew BowdenCompany SecretaryAstraZeneca PLCThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom
On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes, which are a series of four Phase II clinical trials.
20 May 2025 Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html) of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current
In collaboration with general contractor CRB, a life sciences design and construction firm, AstraZeneca embedded operational redundancy and agility into every layer of the facility's architecture.